Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL), making up just under a third of NHL cases. In the U.S., there are roughly 7 cases of DLBCL per 100,000 patients per year, with an average age of presentation at 64 years old. The pathophysiology of DLBCL is complex and not fully understood; but is characterized by a widespread increase of very large, mature B-cells arising from various gene mutations. DLBCL is heterogenous group of tumors and includes many diverse subtypes based on location, presence of other cells within the tumor, and whether the patient has other related illnesses. Advanced age, immunodeficiency, and Epstein-Barr virus are associated risk factors for DLBCL.
The following healthcare professionals: hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with DLBCL.
This program is supported by educational grants from AMGEN.
Release Date: March 16, 2018 -- Expiration Date: March 16, 2020
Faculty: Jonathan Kolitz, MD
Faculty introduction, disclosures
Epidemiology and diagnosis of DLBCL [Learning objective #1]
Management of DLBCL: current guidelines, agents, and monitoring [Learning objectives #2, 3, & 4]
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty: Jonathan E. Kolitz, M.D.
Professor of Medicine
Zucker School of Medicine at Northwell/Hofstra
Monter Cancer Center
Lake Success and Happaugue, NY
Faculty Disclosure: Jonathan Kolitz, MD is on an advisory board for Novartis
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from AMGEN.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Multiple Myeloma Pharmacotherapy: Therapeutic Updates, Best Practices, and Emerging Treatment Options
Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society of Hematology (ASH 2016): Take-Aways, Emerging Practice Changes, and Barriers to their Implementation
Advancing Treatment Strategies in Acute Lymphoblastic Leukemia (ALL) Drug Therapy
Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy